ASP 7713
Alternative Names: ASP7713Latest Information Update: 28 May 2020
At a glance
- Originator Astellas Pharma
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder dysfunction
Most Recent Events
- 28 May 2020 No recent reports of development identified for phase-I development in Bladder-dysfunction(In the elderly, In volunteers, In adults) in United Kingdom (PO)
- 07 Mar 2018 Astellas Pharma completes a phase I trial in Bladder dysfunction (In the elderly, In adults, In volunteers) in United Kingdom (PO) (NCT03108755)
- 25 Oct 2017 Astellas Pharma suspends patient enrolment in a phase I trial in Bladder dysfunction (In the elderly, In adults, In volunteers) due to management decision in United Kingdom (PO) (NCT03108755)